VAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.72 USD | +1.10% |
|
-0.18% | -3.31% |
| Apr. 25 | Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing | MT |
| Apr. 22 | Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,354 | 1,256 | 3,787 | 5,976 | 6,604 | - | - |
| Enterprise Value (EV) 1 | 1,354 | 1,256 | 3,787 | 5,976 | 6,604 | 6,604 | 6,604 |
| P/E ratio | -8.8 x | -12.3 x | -13.9 x | -15.2 x | -14.3 x | -13.5 x | -13 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 308 x |
| EV / Revenue | - | - | - | - | - | - | 308 x |
| EV / EBITDA | -15.4 x | -12.3 x | -16.5 x | -12.9 x | -13.8 x | -13.6 x | - |
| EV / FCF | - | -9.81 x | -57.1 x | -19.1 x | -20.6 x | -16.3 x | -16.3 x |
| FCF Yield | - | -10.2% | -1.75% | -5.24% | -4.85% | -6.12% | -6.12% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 50,950 | 52,785 | 78,980 | 95,154 | 108,759 | - | - |
| Reference price 2 | 26.57 | 23.79 | 47.95 | 62.80 | 60.72 | 60.72 | 60.72 |
| Announcement Date | 3/29/21 | 2/28/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 21.43 |
| EBITDA 1 | - | -88.18 | -101.9 | -229.7 | -464.9 | -480.1 | -484 | - |
| EBIT 1 | - | -89.58 | -103.7 | -232.3 | -468 | -517.2 | -567.7 | -631.6 |
| Operating Margin | - | - | - | - | - | - | - | -2,947.36% |
| Earnings before Tax (EBT) 1 | - | -89.22 | -100.1 | -223.5 | -402.3 | -473.4 | -534.5 | -592.2 |
| Net income 1 | -50.27 | -89.22 | -100.1 | -223.5 | -402.3 | -464.2 | -509.3 | -548.8 |
| Net margin | - | - | - | - | - | - | - | -2,561.11% |
| EPS 2 | -13.24 | -3.020 | -1.930 | -3.440 | -4.140 | -4.246 | -4.510 | -4.679 |
| Free Cash Flow 1 | - | - | -127.9 | -66.37 | -312.9 | -320 | -404.2 | -404.2 |
| FCF margin | - | - | - | - | - | - | - | -1,886.27% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 5/22/20 | 3/29/21 | 2/28/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | -195.8 | - | - | - | - |
| EBIT 1 | -26.95 | -29.85 | -39.22 | -47.89 | -58.58 | -86.57 | -71.19 | -87.15 | -113 | -196.7 | -124 | -125.1 | -129.4 | -139.9 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -26.62 | -28.56 | -38.99 | -48.53 | -57.92 | -78.05 | -60.46 | -68.34 | -92.66 | -180.8 | -125.5 | -123.6 | -127.4 | -142 |
| Net income 1 | -26.62 | -28.56 | -38.99 | -48.53 | -57.92 | -78.05 | -60.46 | -68.34 | -92.66 | -180.8 | -119.9 | -121.6 | -121.3 | -131.1 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.5100 | -0.5400 | -0.6800 | -0.8000 | -0.9300 | -1.020 | -0.7000 | -0.7000 | -0.9100 | -1.820 | -1.129 | -1.119 | -1.106 | -1.189 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 2/28/22 | 5/9/22 | 8/8/22 | 11/7/22 | 2/27/23 | 5/8/23 | 8/8/23 | 11/6/23 | 2/27/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -128 | -66.4 | -313 | -320 | -404 | -404 |
| ROE (net income / shareholders' equity) | - | -44.6% | -17.7% | -36.1% | -36.7% | -34.1% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | -1.580 | -2.340 | -2.630 | -2.990 | -3.120 | -3.090 | - |
| Capex 1 | - | 1.16 | 6.56 | 5.85 | 16.1 | 16.1 | 16.1 | 16.1 |
| Capex / Sales | - | - | - | - | - | - | - | 75.13% |
| Announcement Date | 5/22/20 | 3/29/21 | 2/28/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
60.72
USD
Average target price
103.3
USD
Spread / Average Target
+70.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.31% | 6.6B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PCVX Stock
- Financials Vaxcyte, Inc.
